NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company developing and commercializing non-antibiotic anti-infective products, will host an investment community conference call. Management will discuss the Company’s refined business focus on products for the eye care market announced January 7, 2015, and sales force expansion announced January 20, 2015.
The conference call will feature presentations from the following leading key opinion leaders in the field of eye care, who will be discussing the use of Avenova in their practices:
• Arthur B. Epstein, OD, FAAO, FABCO, FBCLA, DPNAP (2014). Dr. Epstein is co-founder, head of the Dry-Eye–Ocular Surface Disease Center and Director of Clinical Research of the Phoenix Eye Care. He serves as an Adjunct Associate Professor at Midwestern University, Arizona College of Optometry Institute and is the contributing Editor for Review of Optometry, Executive Editor of Review of Cornea and Contact Lenses, and founder and Chief Medical Editor of Optometric Physician. Dr. Epstein has presented more than a 1,000 invited lectures. He is a Fellow of the British Contact Lens Association, a Distinguished Practitioner of the National Academies of Practice, a Fellow of the American and New York Academies of Optometry and a full member of the International Society of Contact Lens Specialists. Dr. Epstein is a member of the NovaBay Optometry Advisory Board.
• Terrence O’Brien, M.D. Dr. O’Brien is an internationally known researcher, clinician and a leading expert in the fields of ocular infectious diseases. He is the Charlotte Breyer Rodgers Chair in Ophthalmology, Director of the Refractive Surgery Service at the Bascom Palmer Eye Institute at Palm Beach Gardens and Professor of Ophthalmology at the University of Miami. He previously served for 15 years as the Tom Clancy Professor of Ophthalmology and Director of Refractive Surgery and Ocular Infectious Diseases at Wilmer Eye Institute of Johns Hopkins University School of Medicine in Baltimore. Dr. O’Brien’s research currently focuses on finding new ways to treat challenging conditions.
DATE: Wednesday, January 21, 2015
TIME: 12:00 p.m. (noon) Eastern time
9:00 a.m. Pacific time
DIAL IN: 866-880-4999 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number 62204781
The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time February 4, 2015, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 62204781. The call will also be archived for 90 days at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: FDA-cleared NEUTROX™ Family of Products: AVENOVA™ for the eye care market, NEUTROPHASE® for wound care and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (Korea), Biopharm (North African and Middle East).
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact T. Paulson